These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36147443)

  • 21. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
    Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
    Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
    Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
    ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
    Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
    Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.
    Taieb J; Price T; Vidot L; Chevallier B; Wyrwicz L; Bachet JB
    BMC Cancer; 2023 Jan; 23(1):94. PubMed ID: 36707808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
    Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
    PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting.
    ELBassiouny M
    Front Oncol; 2023; 13():1112224. PubMed ID: 36937418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
    Weiss L; Karthaus M; Riera-Knorrenschild J; Kretzschmar A; Welslau M; Vehling-Kaiser U; Pelz H; Ettrich TJ; Hess J; Reisländer T; Klein A; Heinemann V;
    ESMO Open; 2022 Feb; 7(1):100391. PubMed ID: 35149429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
    Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
    ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
    Chakrabarti S; Zemla TJ; Ahn DH; Ou FS; Fruth B; Borad MJ; Hartgers ML; Wessling J; Walkes RL; Alberts SR; McWilliams RR; Liu MC; Durgin LM; Bekaii-Saab TS; Mahipal A
    Oncologist; 2020 May; 25(5):380-e763. PubMed ID: 31826977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
    Hayashi K; Furuta M; Furusawa K; Hamaguchi T; Watanabe M; Inokuchi Y; Onuma S; Hashimoto I; Suematsu H; Nagasawa S; Kanematsu K; Yamada T; Notsu A; Ogata T; Oshima T; Machida N; Furuse J; Maeda S
    Anticancer Res; 2023 Jun; 43(6):2831-2840. PubMed ID: 37247885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis.
    Sur D; Lungulescu C; Spînu Ș; Gorzo A; Dumitrescu EA; Gheonea DI; Lungulescu CV
    Front Pharmacol; 2022; 13():1041927. PubMed ID: 36313317
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
    Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer.
    Barone C; Bartolomeo MD; Lonardi S; Maiello E; Martinelli E; Moretto R; Strippoli A; Tamburini E; Zaniboni A; Pinto C
    Future Oncol; 2021 May; 17(14):1749-1759. PubMed ID: 33464133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
    van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
    Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
    Yoshino T; Yamazaki K; Shinozaki E; Komatsu Y; Nishina T; Baba H; Tsuji A; Tsuji Y; Yamaguchi K; Sugimoto N; Denda T; Muro K; Takayama T; Esaki T; Hamamoto Y; Moriwaki T; Shimada Y; Goto M; Nakayama N; Fujii H; Tanase T; Ohtsu A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e719-e732. PubMed ID: 30172759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.
    Patel AK; Duh MS; Barghout V; Yenikomshian MA; Xiao Y; Wynant W; Tabesh M; Fuchs CS
    Clin Colorectal Cancer; 2018 Sep; 17(3):e531-e539. PubMed ID: 29803544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
    Suenaga M; Wakatsuki T; Mashima T; Ogura M; Ichimura T; Shinozaki E; Nakayama I; Osumi H; Ota Y; Takahari D; Chin K; Seimiya H; Yamaguchi K
    Invest New Drugs; 2020 Feb; 38(1):111-119. PubMed ID: 30838483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
    Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
    Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
    Fujimoto Y; Nakanishi R; Nukatsuka M; Matsuoka K; Ando K; Wakasa T; Kitao H; Oki E; Maehara Y; Mori M
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1029-1038. PubMed ID: 32322913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
    Shiroyama M; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Shimada Y; Esaki T; Makiyama A; Moriwaki T
    Sci Rep; 2023 Oct; 13(1):17931. PubMed ID: 37863951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.